A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors
NCT ID: NCT06598371
Last Updated: 2025-12-16
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
PHASE1/PHASE2
Total Enrollment
141 participants
Study Classification
INTERVENTIONAL
Study Start Date
2024-11-21
Study Completion Date
2041-08-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Phase 1 is to find the recommended dose of KSQ-004EX to give to participants with advanced solid tumors.
Phase 2 is to learn if KSQ-004EX at the recommended dose found in Phase1 can help to control advanced solid tumors.
The safety and effects of KSQ-004EX will also be studied in both phases.
Phase 2 is to learn if KSQ-004EX at the recommended dose found in Phase1 can help to control advanced solid tumors.
The safety and effects of KSQ-004EX will also be studied in both phases.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Phase 1: Dose Escalation
Primary Objective:
* To evaluate the safety and tolerability of KSQ-004EX in adult participants with advanced solid tumors (melanoma, NSCLC, HNSCC, CRC, pancreatic cancer, and cervical cancer) Secondary Objectives
* Determine expansion dose
* Assess the safety and tolerability of KSQ-004EX in participants with advanced solid tumors (melanoma, NSCLC, HNSCC, CRC, pancreatic cancer, and cervical cancer)
* Evaluate preliminary anti-tumor activity of KSQ-004EX in participants with advanced solid tumors
* Evaluate the feasibility of the manufacturing process
Phase 2: Expansion Primary Objective
* To assess the anti-tumor activity of KSQ-004EX in participants with advanced malignant solid tumors Secondary Objectives
* Assess the safety and tolerability of KSQ-004EX in participants with advanced solid tumors (melanoma, NSCLC, HNSCC, CRC, pancreatic cancer, and cervical cancer)
* Evaluate anti-tumor activity of KSQ-004EX in participants with advanced malignant solid tumors
* Evaluate overall survival (OS)
* Evaluate the feasibility of the manufacturing process
Primary Objective:
* To evaluate the safety and tolerability of KSQ-004EX in adult participants with advanced solid tumors (melanoma, NSCLC, HNSCC, CRC, pancreatic cancer, and cervical cancer) Secondary Objectives
* Determine expansion dose
* Assess the safety and tolerability of KSQ-004EX in participants with advanced solid tumors (melanoma, NSCLC, HNSCC, CRC, pancreatic cancer, and cervical cancer)
* Evaluate preliminary anti-tumor activity of KSQ-004EX in participants with advanced solid tumors
* Evaluate the feasibility of the manufacturing process
Phase 2: Expansion Primary Objective
* To assess the anti-tumor activity of KSQ-004EX in participants with advanced malignant solid tumors Secondary Objectives
* Assess the safety and tolerability of KSQ-004EX in participants with advanced solid tumors (melanoma, NSCLC, HNSCC, CRC, pancreatic cancer, and cervical cancer)
* Evaluate anti-tumor activity of KSQ-004EX in participants with advanced malignant solid tumors
* Evaluate overall survival (OS)
* Evaluate the feasibility of the manufacturing process
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Select Advanced Solid Tumors
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NON_RANDOMIZED
Intervention Model
SINGLE_GROUP
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Backfill IL-2: Treatment with Lymphodepletion and KSQ-004EX + IL-2
Participants will receive KSQ-004EX and pre-medicated with cyclophosphamide and fludarabine to prevent the lymphodepletion of the chemotherapy.
Group Type
EXPERIMENTAL
Cyclophosphamide
Intervention Type
DRUG
Given by IV
Fludarabine
Intervention Type
DRUG
Given by IV
KSQ-004EX
Intervention Type
DRUG
Given by IV
Interleukin-2
Intervention Type
DRUG
Given by IV
Phase 1 mLDC: Treatment with Modified Lymphodepletion and KSQ-004EX
Participants will receive KSQ-004EX and pre-medicated with cyclophosphamide and fludarabine to prevent the lymphodepletion of the chemotherapy.
Group Type
EXPERIMENTAL
Cyclophosphamide
Intervention Type
DRUG
Given by IV
Fludarabine
Intervention Type
DRUG
Given by IV
KSQ-004EX
Intervention Type
DRUG
Given by IV
Phase 1/Phase 2: Treatment with Lymphodepletion and KSQ-004EX
Participants will receive KSQ-004EX and pre-medicated with cyclophosphamide and fludarabine to prevent the lymphodepletion of the chemotherapy.
Group Type
EXPERIMENTAL
Cyclophosphamide
Intervention Type
DRUG
Given by IV
Fludarabine
Intervention Type
DRUG
Given by IV
KSQ-004EX
Intervention Type
DRUG
Given by IV
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cyclophosphamide
Given by IV
Intervention Type
DRUG
Fludarabine
Given by IV
Intervention Type
DRUG
KSQ-004EX
Given by IV
Intervention Type
DRUG
Interleukin-2
Given by IV
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
IL-2
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Diagnosed with one of the following tumor types:
1. Unresectable, incurable and/or metastatic histologically and/or cytologically confirmed cutaneous, acral, or unknown primary melanoma (Stage IIIC or Stage IV) that has progressed following at least 1 and no more than 3 lines of prior therapy in the advanced/metastatic setting, one of which includes treatment with anti-PD-1/PD-L1 inhibitor alone or in combination with anti-cytotoxic T lymphocyte associated protein 4 (anti-CTLA-4) inhibitor or in combination with anti-LAG-3 antibody.
Note: Up to 5 mucosal patients can be treated in the melanoma expansion cohort only.
2. Histologically and/or cytologically confirmed primary diagnosis of NSCLC which has progressed on at least 1 line and no more than 4 lines of prior therapy in the advanced/metastatic setting, including platinum-based chemotherapy and checkpoint inhibitor therapy (either given in combination or sequentially).
i. Participants with tumors that have known actionable molecular alteration such as epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), ROS-1, B-Raf proto-oncogene (BRAF), rearranged during transfection (RET), MET and Kirsten Rat Sarcoma Virus (KRAS) must have progressed on standard directed molecular therapy in addition to platinum-based chemotherapy.
Note, the following do not count towards a line of prior therapy:
* Any therapy/regimen discontinued due to intolerance/tolerability issues
* Retreatment with the same class or previous class of treatment alone or in combination c. Locally advanced recurrent and/or metastatic histologically and/or cytologically confirmed HNSCC that has been previously treated with at least 1 and no more than 4 lines of prior therapy in the advanced/metastatic setting.
i. Participants must have received a platinum-containing chemotherapy regimen for the treatment of primary tumor in locally advanced, or metastatic setting d. Advanced, metastatic histologically and/or cytologically confirmed colorectal adenocarcinoma that has progressed following at least 1 and no more than 3 lines of prior therapy. Participants with dMMR/MSI-H or KRASG12C BRAF V600E mutation must have progressed on standard directed therapy.
e. Locally advanced, recurrent, or metastatic histologically and/or cytologically confirmed pancreatic ductal adenocarcinoma (PDAC) that has progressed following at least 1 and no more than 3 lines of prior therapy in the advanced/metastatic setting.
f. Recurrent, metastatic, or persistent histologically and/or cytologically confirmed squamous cell carcinoma (SCC), adenosquamous carcinoma, or adenocarcinoma of the cervix that is not amenable to curative treatment with surgery and/or radiation therapy that has progressed following at least 1 and no more than 3 lines of prior therapy in the advanced/metastatic setting.
2. Resectable lesion for KSQ-004EX manufacturing (tumor ≥ 1.5 cm2 or at least 5 core needle biopsies)
3. At least one measurable lesion per RECIST v1.1 (Eisenhauer 2009) following tumor resection for KSQ-004EX manufacturing Note: Lesions in previously irradiated areas should not be selected as a target lesion unless radiation treatment was ≥ 3 months prior, and there has been demonstrated disease progression in the lesion
4. Age ≥ 18 years of age
5. Life expectancy of ≥ 12 weeks
6. Recovered to ≤ Grade 1 or Baseline toxicity (except alopecia, neuropathy, and endocrinopathies from prior immunotherapy) from prior therapy (per the National Cancer Institute \[NCI\] Common Terminology Criteria for Adverse Events \[CTCAE\])
7. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
8. Adequate bone marrow function defined as:
1. Absolute neutrophil count (ANC) of ≥ 1 × 109/L
2. Platelet count of ≥ 100.0 × 109/L
3. Hemoglobin of ≥ 9.0 g/dL
9. Adequate renal function defined as calculated creatinine clearance (Cockcroft-Gault) ≥ 40 mL/min
10. Adequate hepatic function defined as:
1. Total bilirubin ≤ 2.0 × upper limit of normal (ULN) unless associated with Gilbert's syndrome
2. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3.0 × ULN (or ≤ 5 × ULN in patients with liver metastases)
11. Washout period from prior anticancer therapy(ies) of a minimum duration (excluding bridging therapy per concomitant medication, see Section 6.11) is required prior to the first study treatment (i.e., start of LDC therapy) as detailed below:
1. Targeted therapy: prior targeted therapy with an EGFR, ALK, receptor tyrosine kinase, or other-directed agent (eg, erlotinib, afatinib, osimertinib, crizotinib, ceritinib), is allowed provided the washout is a minimum of 7 days or 5 half-lives, whichever is longer prior to start of therapy (LDC)
2. Monoclonal antibodies with a washout of at least 21 days or 5 half-lives or whichever is longer
3. Chemotherapy: adjuvant, neoadjuvant or definitive chemotherapy/chemoradiation is allowed provided the washout is a minimum of 21 days or 5 half-lives, whichever is shorter
4. Radiation therapy: prior external beam radiation is allowed provided a minimum of 14 days have elapsed between the last dose of radiation and first study treatment (LDC)
5. Surgery: previous surgical procedure(s) is permitted provided that wound healing has occurred and at least 14 days have elapsed (for major operative procedures) prior to the first study treatment (LDC)
12. Female participants who are women of childbearing potential (WOCP), (defined as physiologically and anatomically capable of becoming pregnant), confirmed of a negative pregnancy test and agreement to the use of a highly effective contraceptive method or at least 2 effective methods at the same time during study treatment period and for up to 3 months after study treatment (KSQ-004EX infusion). Male participants must be willing to use effective barrier contraception (ie, condoms) during the study treatment period and for up 3 months after study treatment (KSQ-004EX infusion)
a. This includes all female participants, between the onset of menses (as early as 8 years of age) and 55 years unless the participant presents with an applicable exclusionary factor which may be one of the following: i. Postmenopausal (no menses in greater than or equal to 12 consecutive months).
ii. History of hysterectomy or bilateral salpingo-oophorectomy. iii. Ovarian failure (follicle stimulating hormone and estradiol in menopausal range, who have received whole pelvic radiation therapy).
iv. History of bilateral tubal ligation or another surgical sterilization procedure.
b. Approved methods of birth control are as follows: hormonal contraception (ie, birth control pills, injection, implant, transdermal patch, vaginal ring), intrauterine device (IUD), tubal Ligation or hysterectomy, subject/partner post-vasectomy, implantable or injectable contraceptives, and condoms plus spermicide. Not engaging in sexual activity for the total duration of the trial and the drug washout period is an acceptable practice; however periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.
13. Ability to understand and the willingness to sign a written informed consent document
14. Signed and dated Institutional Review Board (IRB) approved informed consent form (ICF) before any protocol-directed Screening procedures are performed
1. Unresectable, incurable and/or metastatic histologically and/or cytologically confirmed cutaneous, acral, or unknown primary melanoma (Stage IIIC or Stage IV) that has progressed following at least 1 and no more than 3 lines of prior therapy in the advanced/metastatic setting, one of which includes treatment with anti-PD-1/PD-L1 inhibitor alone or in combination with anti-cytotoxic T lymphocyte associated protein 4 (anti-CTLA-4) inhibitor or in combination with anti-LAG-3 antibody.
Note: Up to 5 mucosal patients can be treated in the melanoma expansion cohort only.
2. Histologically and/or cytologically confirmed primary diagnosis of NSCLC which has progressed on at least 1 line and no more than 4 lines of prior therapy in the advanced/metastatic setting, including platinum-based chemotherapy and checkpoint inhibitor therapy (either given in combination or sequentially).
i. Participants with tumors that have known actionable molecular alteration such as epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), ROS-1, B-Raf proto-oncogene (BRAF), rearranged during transfection (RET), MET and Kirsten Rat Sarcoma Virus (KRAS) must have progressed on standard directed molecular therapy in addition to platinum-based chemotherapy.
Note, the following do not count towards a line of prior therapy:
* Any therapy/regimen discontinued due to intolerance/tolerability issues
* Retreatment with the same class or previous class of treatment alone or in combination c. Locally advanced recurrent and/or metastatic histologically and/or cytologically confirmed HNSCC that has been previously treated with at least 1 and no more than 4 lines of prior therapy in the advanced/metastatic setting.
i. Participants must have received a platinum-containing chemotherapy regimen for the treatment of primary tumor in locally advanced, or metastatic setting d. Advanced, metastatic histologically and/or cytologically confirmed colorectal adenocarcinoma that has progressed following at least 1 and no more than 3 lines of prior therapy. Participants with dMMR/MSI-H or KRASG12C BRAF V600E mutation must have progressed on standard directed therapy.
e. Locally advanced, recurrent, or metastatic histologically and/or cytologically confirmed pancreatic ductal adenocarcinoma (PDAC) that has progressed following at least 1 and no more than 3 lines of prior therapy in the advanced/metastatic setting.
f. Recurrent, metastatic, or persistent histologically and/or cytologically confirmed squamous cell carcinoma (SCC), adenosquamous carcinoma, or adenocarcinoma of the cervix that is not amenable to curative treatment with surgery and/or radiation therapy that has progressed following at least 1 and no more than 3 lines of prior therapy in the advanced/metastatic setting.
2. Resectable lesion for KSQ-004EX manufacturing (tumor ≥ 1.5 cm2 or at least 5 core needle biopsies)
3. At least one measurable lesion per RECIST v1.1 (Eisenhauer 2009) following tumor resection for KSQ-004EX manufacturing Note: Lesions in previously irradiated areas should not be selected as a target lesion unless radiation treatment was ≥ 3 months prior, and there has been demonstrated disease progression in the lesion
4. Age ≥ 18 years of age
5. Life expectancy of ≥ 12 weeks
6. Recovered to ≤ Grade 1 or Baseline toxicity (except alopecia, neuropathy, and endocrinopathies from prior immunotherapy) from prior therapy (per the National Cancer Institute \[NCI\] Common Terminology Criteria for Adverse Events \[CTCAE\])
7. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
8. Adequate bone marrow function defined as:
1. Absolute neutrophil count (ANC) of ≥ 1 × 109/L
2. Platelet count of ≥ 100.0 × 109/L
3. Hemoglobin of ≥ 9.0 g/dL
9. Adequate renal function defined as calculated creatinine clearance (Cockcroft-Gault) ≥ 40 mL/min
10. Adequate hepatic function defined as:
1. Total bilirubin ≤ 2.0 × upper limit of normal (ULN) unless associated with Gilbert's syndrome
2. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3.0 × ULN (or ≤ 5 × ULN in patients with liver metastases)
11. Washout period from prior anticancer therapy(ies) of a minimum duration (excluding bridging therapy per concomitant medication, see Section 6.11) is required prior to the first study treatment (i.e., start of LDC therapy) as detailed below:
1. Targeted therapy: prior targeted therapy with an EGFR, ALK, receptor tyrosine kinase, or other-directed agent (eg, erlotinib, afatinib, osimertinib, crizotinib, ceritinib), is allowed provided the washout is a minimum of 7 days or 5 half-lives, whichever is longer prior to start of therapy (LDC)
2. Monoclonal antibodies with a washout of at least 21 days or 5 half-lives or whichever is longer
3. Chemotherapy: adjuvant, neoadjuvant or definitive chemotherapy/chemoradiation is allowed provided the washout is a minimum of 21 days or 5 half-lives, whichever is shorter
4. Radiation therapy: prior external beam radiation is allowed provided a minimum of 14 days have elapsed between the last dose of radiation and first study treatment (LDC)
5. Surgery: previous surgical procedure(s) is permitted provided that wound healing has occurred and at least 14 days have elapsed (for major operative procedures) prior to the first study treatment (LDC)
12. Female participants who are women of childbearing potential (WOCP), (defined as physiologically and anatomically capable of becoming pregnant), confirmed of a negative pregnancy test and agreement to the use of a highly effective contraceptive method or at least 2 effective methods at the same time during study treatment period and for up to 3 months after study treatment (KSQ-004EX infusion). Male participants must be willing to use effective barrier contraception (ie, condoms) during the study treatment period and for up 3 months after study treatment (KSQ-004EX infusion)
a. This includes all female participants, between the onset of menses (as early as 8 years of age) and 55 years unless the participant presents with an applicable exclusionary factor which may be one of the following: i. Postmenopausal (no menses in greater than or equal to 12 consecutive months).
ii. History of hysterectomy or bilateral salpingo-oophorectomy. iii. Ovarian failure (follicle stimulating hormone and estradiol in menopausal range, who have received whole pelvic radiation therapy).
iv. History of bilateral tubal ligation or another surgical sterilization procedure.
b. Approved methods of birth control are as follows: hormonal contraception (ie, birth control pills, injection, implant, transdermal patch, vaginal ring), intrauterine device (IUD), tubal Ligation or hysterectomy, subject/partner post-vasectomy, implantable or injectable contraceptives, and condoms plus spermicide. Not engaging in sexual activity for the total duration of the trial and the drug washout period is an acceptable practice; however periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.
13. Ability to understand and the willingness to sign a written informed consent document
14. Signed and dated Institutional Review Board (IRB) approved informed consent form (ICF) before any protocol-directed Screening procedures are performed
Exclusion Criteria
1. Prior organ allograft or prior cell therapy that included LDC or myeloablative chemotherapy regimen
2. Known hypersensitivity to any component of KSQ-004EX or excipient including dimethyl sulfoxide, human serum albumin, LDC regimen (cyclophosphamide or fludarabine) or IL-2 (as applicable)
3. Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease \[eg, Grade ≥ 2 colitis or Crohn's disease\], systemic lupus erythematosus, sarcoidosis syndrome, or Wegener syndrome \[granulomatosis with polyangiitis\], rheumatoid arthritis, etc.\]). The following are exceptions to this criterion:
1. Participants with vitiligo or alopecia
2. Participants with hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement
3. Any chronic skin condition that does not require systemic therapy
4. Participants with celiac disease controlled by diet alone
4. Hypersensitivity to antibiotics of the aminoglycoside group (eg, streptomycin, gentamicin) or penicillin
5. Active, uncontrolled concurrent infection requiring IV antibiotics present at Screening
6. Uveal and/or ocular melanoma
7. Large cell neuroendocrine NSCLC (defined as pathology with \>10% neuroendocrine components)
8. Symptomatic and/or untreated brain metastases (of any size or number) including active leptomeningeal or parenchymal metastases.
Note: Participants with definitively treated brain metastases may be considered for enrollment if stable (defined as stable for 1-month post-central nervous system directed therapy) after discussion with the drug provider (KSQ)
9. Participants with ascites
10. Women who are pregnant or nursing
11. Seropositive for human immunodeficiency virus (HIV) 1 or 2 or acquired immunodeficiency syndrome, or active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV) Note: Participants with positive HCV antibody may be eligible if HCV ribonucleic acid (RNA) is undetectable on a quantitative HCV RNA assay, following discussion with the drug provider (KSQ)
12. Any form of primary immunodeficiency (eg, Severe Combined Immunodeficiency Disease)
13. Any known clinically significant or concurrent acute liver disease, including viral hepatitis
14. Previous solid organ or hematopoietic cell transplant
15. Need for treatment with steroids at stable doses (\> 10 mg/day prednisone or equivalent)
1. Topical, ophthalmic, or inhaled steroid medications are allowed
2. Systemic steroid (\>10 mg/day) use is not allowed for 14 days prior to enrollment
3. Systemic steroids \< 10 mg/day are permitted if for supplemental endocrine only Note: steroids can be administered for IV contrast allergy
16. Live or unattenuated vaccine \< 28 days prior to first dose of LDC regimen
17. History of stroke, transient ischemic attack, unstable angina, or myocardial infarction, within 3 months prior to first dose of study treatment
18. Symptomatic congestive heart failure according to New York Heart Association (NYHA) classification, Class III or IV (per NYHA Classification), unstable angina pectoris, clinically significant cardia arrhythmia, or left ventricular ejection fraction \< 45%
19. Prolongation of QT/QTc interval (QTc interval \> 480 msec) using the Frederica method of QTc analysis
20. Unable to walk a distance of 80% predicted for age and sex or develop hypoxia (SPO2 \< 90%) during a 6-minute walk test (this test can be performed in place of pulmonary function test \[PFT\] for those unable to perform a reliable PFT due to complex upper airway anatomy)
21. For participants receiving IL-2 only: evidence of ischemia on cardiac stress test
22. \> 80% stenosis based on carotid doppler ultrasound for patients with NSCLC and HNSCC with \> 35 pack year smoking history
23. Obstructive or restrictive pulmonary disease Note: Post-bronchodilator values: forced expiratory volume (FEV1)/forced vital capacity \> 70% or FEV1 \> 50% of predicted normal are required for study entry
24. Suspected pneumonitis or interstitial lung disease (confirmed by radiography or computed tomography \[CT\])
25. Treatment on another study with other investigational therapeutic interventional study within 28 days to start of LDC regimen
26. Known additional malignancy that is active and/or progressive requiring treatment; exceptions including basal cell or squamous cell skin cancer, or other cancer for which the participants has been disease-free for at least 2 years
27. Psychiatric illness/social situation that would limit compliance with study requirements, as determined by the Investigator
28. Other severe, acute, or chronic medical condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or that may interfere with the interpretation of the study results, and in the judgement of the Investigator, would the participant inappropriate for the study
2. Known hypersensitivity to any component of KSQ-004EX or excipient including dimethyl sulfoxide, human serum albumin, LDC regimen (cyclophosphamide or fludarabine) or IL-2 (as applicable)
3. Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease \[eg, Grade ≥ 2 colitis or Crohn's disease\], systemic lupus erythematosus, sarcoidosis syndrome, or Wegener syndrome \[granulomatosis with polyangiitis\], rheumatoid arthritis, etc.\]). The following are exceptions to this criterion:
1. Participants with vitiligo or alopecia
2. Participants with hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement
3. Any chronic skin condition that does not require systemic therapy
4. Participants with celiac disease controlled by diet alone
4. Hypersensitivity to antibiotics of the aminoglycoside group (eg, streptomycin, gentamicin) or penicillin
5. Active, uncontrolled concurrent infection requiring IV antibiotics present at Screening
6. Uveal and/or ocular melanoma
7. Large cell neuroendocrine NSCLC (defined as pathology with \>10% neuroendocrine components)
8. Symptomatic and/or untreated brain metastases (of any size or number) including active leptomeningeal or parenchymal metastases.
Note: Participants with definitively treated brain metastases may be considered for enrollment if stable (defined as stable for 1-month post-central nervous system directed therapy) after discussion with the drug provider (KSQ)
9. Participants with ascites
10. Women who are pregnant or nursing
11. Seropositive for human immunodeficiency virus (HIV) 1 or 2 or acquired immunodeficiency syndrome, or active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV) Note: Participants with positive HCV antibody may be eligible if HCV ribonucleic acid (RNA) is undetectable on a quantitative HCV RNA assay, following discussion with the drug provider (KSQ)
12. Any form of primary immunodeficiency (eg, Severe Combined Immunodeficiency Disease)
13. Any known clinically significant or concurrent acute liver disease, including viral hepatitis
14. Previous solid organ or hematopoietic cell transplant
15. Need for treatment with steroids at stable doses (\> 10 mg/day prednisone or equivalent)
1. Topical, ophthalmic, or inhaled steroid medications are allowed
2. Systemic steroid (\>10 mg/day) use is not allowed for 14 days prior to enrollment
3. Systemic steroids \< 10 mg/day are permitted if for supplemental endocrine only Note: steroids can be administered for IV contrast allergy
16. Live or unattenuated vaccine \< 28 days prior to first dose of LDC regimen
17. History of stroke, transient ischemic attack, unstable angina, or myocardial infarction, within 3 months prior to first dose of study treatment
18. Symptomatic congestive heart failure according to New York Heart Association (NYHA) classification, Class III or IV (per NYHA Classification), unstable angina pectoris, clinically significant cardia arrhythmia, or left ventricular ejection fraction \< 45%
19. Prolongation of QT/QTc interval (QTc interval \> 480 msec) using the Frederica method of QTc analysis
20. Unable to walk a distance of 80% predicted for age and sex or develop hypoxia (SPO2 \< 90%) during a 6-minute walk test (this test can be performed in place of pulmonary function test \[PFT\] for those unable to perform a reliable PFT due to complex upper airway anatomy)
21. For participants receiving IL-2 only: evidence of ischemia on cardiac stress test
22. \> 80% stenosis based on carotid doppler ultrasound for patients with NSCLC and HNSCC with \> 35 pack year smoking history
23. Obstructive or restrictive pulmonary disease Note: Post-bronchodilator values: forced expiratory volume (FEV1)/forced vital capacity \> 70% or FEV1 \> 50% of predicted normal are required for study entry
24. Suspected pneumonitis or interstitial lung disease (confirmed by radiography or computed tomography \[CT\])
25. Treatment on another study with other investigational therapeutic interventional study within 28 days to start of LDC regimen
26. Known additional malignancy that is active and/or progressive requiring treatment; exceptions including basal cell or squamous cell skin cancer, or other cancer for which the participants has been disease-free for at least 2 years
27. Psychiatric illness/social situation that would limit compliance with study requirements, as determined by the Investigator
28. Other severe, acute, or chronic medical condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or that may interfere with the interpretation of the study results, and in the judgement of the Investigator, would the participant inappropriate for the study
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
KSQ Therapeutics, Inc.
INDUSTRY
Sponsor Role
collaborator
M.D. Anderson Cancer Center
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Rodabe N Amaria, MD
Role: PRINCIPAL_INVESTIGATOR
M.D. Anderson Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
MD Anderson Cancer Center
Houston, Texas, United States
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
United States
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Related Links
Access external resources that provide additional context or updates about the study.
https://www.mdanderson.org
MD Anderson Cancer Center
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2024-07763
Identifier Type: OTHER
Identifier Source: secondary_id
2024-0397
Identifier Type: -
Identifier Source: org_study_id